Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1403"
| Predicate | Value (sorted: default) |
|---|---|
| rdfs:label | |
| rdf:type | |
| ?:Evidence_assump_list_id |
"240"
|
| ?:Evidence_enzyme_system | |
| ?:Evidence_type | |
| ?:claim_assumed_valid_for_evidence_application_evidence_1230 | |
| ?:content |
"Route of administration: oral
polymorphic enzyme: NO
study duration: 5 days
population: 5 male, 5 female
ages:21-35
dose: 200mg itraconazole 1xday for 5 days, a single dose of 40 mg atorvastatin on day 4.
(mean AUC_i)/(mean AUC) = 179.7/24.2 (AUC is 0-infinity)
NOTE: three females were on contraceptive steroids
description:
In a randomized, double-blind, two-phase crossover study, 10 healthy volunteers took 200 mg itraconazole or matched placebo orally once daily for 4 days. On day 4, 40 mg atorvastatin was administered orally, and a further dose of 200 mg itraconazole or placebo was taken 24 hours after atorvastatin intake. Serum concentrations of atorvastatin acid, atorvastatin lactone, 2-hydroxyatorvastatin acid and lactone, 4-hydroxyatorvastatin acid and lactone, active and total HMG-CoA reductase inhibitors, itraconazole, and hydroxyitraconazole were measured up to 72 hours. RESULTS: Itraconazole increased the area under the concentration--time curve from time zero to 72 hours [AUC(0-72)] and the elimination half-life of atorvastatin acid about threefold (p < 0.001), whereas the peak serum concentration was not significantly changed. The AUC(0-72) of atorvastatin lactone was increased about fourfold (p < 0.001), and the peak serum concentration and half-life were increased more than twofold (p < 0.01)."
|
| dc:creator | |
| dc:date |
"09/24/2007 09:59:20"
|
| rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ atorvastatin_primary_total_clearance_enzyme_cyp3a4, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1230 }